Medical Pharmacology: Chapter 34 — Anti-Cancer Drugs Part II -- Module 2 — Targeted Small Molecule Inhibitors: Core Concepts

Chapter 34 — Anti-Cancer Drugs Part II — Module 2 — Targeted Small Molecule Inhibitors: Core Concepts

1. BRAF is a kinase in a signaling chain (the MAPK pathway) that tells a cell to grow and divide. Some melanomas carry a specific BRAF mutation (called V600E) that locks this signal on, and BRAF inhibitor drugs are designed to switch it back off. However, giving a BRAF inhibitor to a tumor that instead carries a RAS mutation (a different gene one step upstream in the same pathway) produces an unexpected result. What happens?

A) The drug binds the mutated RAS protein directly and shuts the pathway down more completely than in BRAF-mutant tumors
B) The drug has no effect of any kind because RAS sits upstream of where the drug acts
C) The drug paradoxically activates the growth pathway and can accelerate tumor growth
D) The drug converts the RAS mutation into a BRAF V600E mutation, restoring sensitivity
E) The drug triggers immediate tumor cell death regardless of which gene is mutated

ANSWER: C

Rationale:

In a RAS-mutant tumor, a BRAF inhibitor does not silence the MAPK growth pathway — it paradoxically activates it. The drug promotes pairing of BRAF with its relative RAF protein, and in the presence of active mutant RAS this drug-bound complex drives downstream signaling harder rather than shutting it off, which can accelerate tumor growth. This is why BRAF V600E mutation status must be confirmed before a BRAF inhibitor is started, and why BRAF inhibitor monotherapy is prohibited in RAS-mutant tumors. Option C correctly captures this paradoxical activation.

Option A: Option A is incorrect because BRAF inhibitors do not bind RAS at all, and they certainly do not work better in RAS-mutant tumors.
Option B: Option B is incorrect because the drug is far from inert in this setting — the problem is not absence of effect but a harmful effect.
Option D: Option D is incorrect because drugs do not convert one gene mutation into another; mutation status is fixed in the tumor.
Option E: Option E is incorrect because BRAF inhibitors do not kill cells indiscriminately — their effect depends entirely on the underlying mutation, which is the entire point of the question.

2. CDK4/6 inhibitors (drugs such as palbociclib used in breast cancer; CDK4/6 are cell-cycle enzymes that push cells from a resting phase into division) share one dominant blood-related side effect. Knowing that these drugs work by halting cell division rather than by poisoning the bone marrow, which laboratory finding is the characteristic, expected toxicity?

A) Neutropenia (a low neutrophil count) that is typically non-febrile and recovers quickly when the drug is paused
B) Severe irreversible aplastic anemia requiring lifelong transfusion
C) A rising platelet count (thrombocytosis) from marrow overstimulation
D) Profound hemolysis with dark urine within hours of the first dose
E) A complete absence of any effect on blood counts at any dose

ANSWER: A

Rationale:

Neutropenia is the dominant, expected toxicity of CDK4/6 inhibitors, and its character follows directly from the mechanism. Because these drugs arrest the division of neutrophil precursors rather than destroying the marrow, the neutropenia is cytostatic — it is usually non-febrile and reverses within one to two weeks of holding the drug, which is why these agents are commonly dosed three weeks on and one week off to allow recovery. This choice captures both the finding and its reversible, non-aplastic nature.

Option B: Option B is incorrect because the marrow is not destroyed; the effect is a temporary pause in production, not aplasia.
Option C: Option C is incorrect because the drugs suppress, not stimulate, blood cell production, so platelet counts do not rise.
Option D: Option D is incorrect because CDK4/6 inhibitors do not cause hemolysis; that pattern points to a different mechanism entirely.
Option E: Option E is incorrect because a measurable, predictable drop in neutrophils is precisely what these drugs cause and what monitoring is designed to catch.

3. Venetoclax blocks BCL-2, a protein that cancer cells (such as those in chronic lymphocytic leukemia) use to avoid programmed cell death. When the drug is given, large numbers of tumor cells can die at the same time, spilling their contents into the bloodstream — a metabolic emergency called tumor lysis syndrome. Which strategy is used specifically to prevent this complication when starting the drug?

A) Giving the full target dose on day one to clear tumor cells as fast as possible
B) Withholding all fluids to concentrate the drug at the tumor site
C) Adding a second BCL-2 inhibitor to double the rate of cell death
D) A gradual dose ramp-up over several weeks with hydration and uric-acid-lowering prophylaxis
E) Pretreating with a drug that prevents any tumor cells from dying

ANSWER: D

Rationale:

Tumor lysis syndrome is the defining hazard of venetoclax precisely because the drug triggers rapid, synchronous death of a large burden of BCL-2-dependent tumor cells, releasing potassium, phosphate, and uric acid fast enough to cause kidney injury, arrhythmia, and seizures within hours. The countermeasure is to slow the kill: a mandatory stepwise dose ramp-up over roughly five weeks, paired with aggressive hydration, uric-acid-lowering prophylaxis (such as allopurinol), and close laboratory monitoring after each increase. This is the strategy described in the correct choice.

Option A: Option A is incorrect and dangerous because giving the full dose immediately maximizes the very simultaneous cell death that causes the syndrome.
Option B: Option B is incorrect because dehydration worsens tumor lysis syndrome — hydration is protective, not harmful.
Option C: Option C is incorrect because adding a second agent that accelerates cell death would increase, not reduce, the metabolic load.
Option E: Option E is incorrect because the therapeutic goal is to kill tumor cells; the strategy is to control the rate of death, not to prevent it.

4. PARP inhibitors (drugs such as olaparib) block PARP, an enzyme that repairs single-strand breaks in DNA. They are used specifically in tumors carrying BRCA1/2 mutations (BRCA genes run a separate, back-up DNA repair system called homologous recombination). Why does blocking PARP selectively kill these particular tumor cells while sparing normal cells?

A) PARP inhibitors directly cut the tumor DNA into fragments that cannot be reassembled
B) The tumor cell has lost its back-up repair system, so blocking the remaining repair enzyme leaves it unable to fix DNA and it dies
C) PARP inhibitors restore the missing BRCA repair function, forcing the cell to over-repair until it ruptures
D) Normal cells lack PARP entirely, so only tumor cells are exposed to the drug
E) The drug works equally on all cells and has no relationship to BRCA status

ANSWER: B

Rationale:

This is the concept of synthetic lethality. A BRCA-mutant tumor cell has already lost its homologous-recombination back-up repair pathway; it survives by relying on PARP-mediated repair. When a PARP inhibitor removes that remaining pathway, the cell is left with no way to fix accumulating DNA damage and dies. A normal cell still has intact BRCA-dependent repair, so it tolerates PARP inhibition — two individually survivable deficiencies combine to be lethal only in the tumor. This mechanism is what the correct choice describes.

Option A: Option A is incorrect because PARP inhibitors do not cut DNA; they prevent repair of breaks that arise normally.
Option C: Option C is incorrect because the drugs do not restore BRCA function — selectivity depends on that function being absent in the tumor.
Option D: Option D is incorrect because normal cells do express PARP and are exposed to the drug; they survive because their back-up repair is intact, not because they lack the target.
Option E: Option E is incorrect because the entire rationale for these drugs is their dependence on BRCA/homologous-recombination status.

5. Bortezomib is a proteasome inhibitor (the proteasome is the cell's protein-recycling machine; multiple myeloma cells are especially dependent on it) used in multiple myeloma. Its dose-limiting toxicity is a painful sensory peripheral neuropathy. A simple change in how the drug is given substantially lowers the rate of this nerve injury while keeping drug exposure the same. What is that change?

A) Doubling the intravenous dose to shorten the treatment course
B) Giving the drug only with a high-fat meal
C) Combining it with a second proteasome inhibitor
D) Switching from once-weekly to twice-daily dosing
E) Administering the drug subcutaneously rather than intravenously

ANSWER: E

Rationale:

Bortezomib-associated peripheral neuropathy is its dose-limiting and cumulative toxicity, and subcutaneous administration markedly reduces it — roughly halving the rate of higher-grade neuropathy — while producing equivalent systemic drug exposure to the intravenous route. For this reason the subcutaneous route is preferred in all eligible patients. This is the change named in the correct choice.

Option A: Option A is incorrect because raising the intravenous dose would increase neuropathy, not reduce it.
Option B: Option B is incorrect because food timing does not govern bortezomib neuropathy; that consideration applies to certain oral agents, not to this injectable drug's nerve toxicity.
Option C: Option C is incorrect because adding a second proteasome inhibitor adds toxicity rather than sparing the nerves.
Option D: Option D is incorrect because the neuropathy-sparing maneuver is reducing dosing frequency (weekly rather than twice weekly), not increasing it to twice daily, which would worsen cumulative exposure.

6. The immunomodulatory drugs (IMiDs) — thalidomide and its relatives lenalidomide and pomalidomide — are used in multiple myeloma. One property of this entire class is so serious that, in the United States, prescribing them requires enrollment in a formal safety program with mandatory pregnancy testing and two forms of contraception. Which property is responsible for these requirements?

A) Severe teratogenicity — the capacity to cause major birth defects if taken during pregnancy
B) A tendency to cause sudden permanent hearing loss
C) Conversion of the drug into a controlled opioid in the body
D) An ability to render standard contraceptive pills ineffective by raising their clearance
E) A high risk of triggering immediate anaphylaxis on first exposure

ANSWER: A

Rationale:

The IMiDs are powerfully teratogenic; thalidomide historically caused severe limb and cardiac malformations, and the class as a whole can produce major birth defects after even limited exposure during the window of fetal development. This is the reason all three require a risk-management program mandating prescriber and patient enrollment, two forms of contraception, regular pregnancy testing, and a limited dispensing window. This is the property identified in the correct choice.

Option B: Option B is incorrect because sudden hearing loss is not the defining class hazard driving these programs.
Option C: Option C is incorrect because IMiDs are not metabolized into opioids and carry no such controlled-substance conversion.
Option D: Option D is incorrect because the safety requirement exists because the drug harms a fetus, not because it weakens contraceptives; in fact two contraceptive methods are required specifically to prevent pregnancy.
Option E: Option E is incorrect because the programs target teratogenic risk over an entire pregnancy, not an acute allergic reaction.

7. Ibrutinib is a BTK inhibitor (BTK is a signaling enzyme that B-cell cancers such as chronic lymphocytic leukemia depend on for survival). Beyond effects you might expect from immune suppression, ibrutinib has a characteristic cardiac rhythm side effect that distinguishes it within this drug class. Which arrhythmia is most characteristically associated with ibrutinib?

A) Complete heart block requiring a permanent pacemaker
B) Sustained ventricular tachycardia from direct myocardial scarring
C) Atrial fibrillation, attributed to off-target effects on cardiac signaling rather than structural heart damage
D) A dangerously slow sinus bradycardia from vagal overactivity
E) No effect on cardiac rhythm of any kind

ANSWER: C

Rationale:

Atrial fibrillation is the characteristic rhythm disturbance associated with ibrutinib, occurring more often with ibrutinib than with the more selective second-generation BTK inhibitors. It is thought to arise from off-target inhibition of kinases that regulate atrial cell calcium handling, rather than from structural cardiomyopathy. The correct choice states both the arrhythmia and its non-structural basis.

Option A: Option A is incorrect because ibrutinib is not associated with high-grade conduction block.
Option B: Option B is incorrect because the drug does not produce myocardial scarring, and ventricular tachycardia from scarring is not its signature effect.
Option D: Option D is incorrect because ibrutinib is linked to a fast, irregular atrial rhythm, not vagally mediated bradycardia.
Option E: Option E is incorrect because a clinically important arrhythmia is precisely what makes ibrutinib notable among BTK inhibitors.

8. IDH inhibitors (ivosidenib and enasidenib; IDH is a mutated metabolic enzyme in some acute myeloid leukemias) work not by killing leukemia cells directly but by forcing immature blast cells to mature. This mechanism produces a characteristic, potentially life-threatening complication marked by fever, shortness of breath, and lung infiltrates. What is this complication, and what is the immediate treatment?

A) An acute allergic reaction treated with epinephrine
B) Differentiation syndrome, treated promptly with corticosteroids
C) Tumor lysis syndrome, treated with a uric-acid-lowering agent
D) Septic shock, treated with broad-spectrum antibiotics alone
E) A drug-induced asthma attack treated with inhaled bronchodilators

ANSWER: B

Rationale:

Because IDH inhibitors drive leukemic blasts to differentiate rather than killing them outright, a wave of maturing cells can release inflammatory signals, producing differentiation syndrome — fever, dyspnea, pulmonary infiltrates, low blood pressure, and edema, typically in the first weeks of therapy. The treatment is prompt corticosteroids (such as dexamethasone), started without waiting for confirmation because delayed treatment raises mortality. The correct choice names both the syndrome and its treatment.

Option A: Option A is incorrect because this is an inflammatory consequence of forced cell maturation, not an IgE-mediated allergic reaction, and epinephrine is not the treatment.
Option C: Option C is incorrect because tumor lysis syndrome reflects rapid cell death with metabolic derangements, whereas differentiation syndrome reflects cell maturation with inflammation; the IDH inhibitor mechanism produces the latter.
Option D: Option D is incorrect because, although infection must be considered, the defining entity here is differentiation syndrome and corticosteroids are essential — antibiotics alone would miss the diagnosis.
Option E: Option E is incorrect because the pulmonary findings stem from an inflammatory infiltrative process, not bronchospasm, and bronchodilators are not the answer.

9. Everolimus is an mTOR inhibitor (mTOR is a central enzyme controlling cell growth and protein production). Among its toxicities, two are especially characteristic of the mTOR inhibitor class and frequently appear together on examinations. Which pairing correctly lists two signature toxicities of mTOR inhibitors?

A) Hearing loss and color blindness
B) Hair regrowth and weight gain
C) Profuse watery diarrhea and tooth discoloration
D) Mouth ulcers (stomatitis) and non-infectious inflammation of the lungs (pneumonitis)
E) Joint fusion and bone overgrowth

ANSWER: D

Rationale:

The mTOR inhibitors are classically associated with stomatitis (painful oral mucosal ulcers, often managed with a corticosteroid mouthwash) and non-infectious pneumonitis (an inflammatory lung process presenting with cough or breathlessness and ground-glass changes, managed by holding the drug and giving corticosteroids if symptomatic). This pairing is the one given in the correct choice.

Option A: Option A is incorrect because hearing loss and color blindness are not characteristic mTOR inhibitor effects.
Option B: Option B is incorrect because these drugs do not cause beneficial hair regrowth or weight gain as signature effects; the relevant toxicities are mucosal and pulmonary.
Option C: Option C is incorrect because, although gastrointestinal upset can occur, the examination-defining pairing is stomatitis and pneumonitis, not diarrhea with tooth discoloration.
Option E: Option E is incorrect because skeletal fusion and bone overgrowth are unrelated to mTOR inhibition.

10. Alpelisib inhibits PI3K-alpha, one form of an enzyme in a major growth pathway. PI3K-alpha also happens to be the enzyme that insulin uses inside cells to drive glucose uptake. A clinician starting alpelisib should therefore anticipate and monitor for which predictable metabolic effect?

A) A dangerous drop in blood sodium
B) A fall in blood glucose requiring sugar supplementation
C) A rise in blood calcium causing kidney stones
D) A drop in blood potassium causing muscle weakness
E) A rise in blood glucose (hyperglycemia) from impaired insulin signaling

ANSWER: E

Rationale:

This question connects mechanism to a bedside consequence. Because insulin relies on PI3K-alpha to move glucose into fat, liver, and muscle, blocking PI3K-alpha blunts insulin's action and produces insulin resistance — so hyperglycemia is the predictable, common, and characteristic toxicity of alpelisib, and fasting glucose is monitored before each cycle. Option E links the blocked insulin signaling to the rise in glucose.

Option A: Option A is incorrect because alpelisib's signature metabolic effect is on glucose, not sodium.
Option B: Option B is incorrect and inverts the physiology: impairing insulin's pathway raises glucose rather than lowering it.
Option C: Option C is incorrect because calcium handling is not driven by PI3K-alpha and is not the expected effect.
Option D: Option D is incorrect because potassium depletion is not the characteristic metabolic toxicity of this drug; the predictable problem is hyperglycemia.

11. Bortezomib and carfilzomib are both proteasome inhibitors used in multiple myeloma, but they differ in their dominant toxicities. Bortezomib's main dose-limiting problem is peripheral neuropathy. Carfilzomib causes much less neuropathy but is distinguished by a different organ toxicity that requires baseline cardiac assessment and careful hydration. Which toxicity distinguishes carfilzomib?

A) Cardiovascular toxicity, including heart failure and hypertension
B) Severe hearing loss
C) Permanent loss of the sense of smell
D) Progressive joint destruction
E) Chronic constipation as the dose-limiting effect

ANSWER: A

Rationale:

This question asks the student to discriminate between two closely related agents. Carfilzomib is set apart from bortezomib by cardiovascular toxicity — cardiomyopathy and heart failure, hypertension, and a higher rate of arterial events — which is why baseline cardiac evaluation and careful hydration around infusions are required and why patients with advanced heart failure are excluded. This distinguishing toxicity is the one named in the correct choice.

Option B: Option B is incorrect because hearing loss is not the carfilzomib-defining problem.
Option C: Option C is incorrect because loss of smell is unrelated to either proteasome inhibitor.
Option D: Option D is incorrect because joint destruction is not characteristic of carfilzomib.
Option E: Option E is incorrect because, while constipation can accompany neuropathy with bortezomib, it is not carfilzomib's distinguishing toxicity — the cardiovascular profile is.

12. A patient with multiple myeloma is started on lenalidomide together with dexamethasone. Beyond their effects on the cancer, immunomodulatory drugs raise the risk of blood clots forming in the veins, and this risk is increased further when they are combined with steroids. Because of this, what additional medication should be prescribed alongside the regimen?

A) A drug to raise the blood pressure
B) A medication to thin the bones
C) A blood-clot-prevention agent, such as aspirin or an anticoagulant, chosen by the patient's clot risk
D) A high-dose antihistamine taken daily
E) An additional immunomodulatory drug to balance the first

ANSWER: C

Rationale:

This question connects a class property to a required co-prescription. Immunomodulatory drugs carry a class-wide risk of venous thromboembolism, and combining them with dexamethasone amplifies that risk, so thromboprophylaxis is mandatory: aspirin for lower-risk patients and a therapeutic anticoagulant for higher-risk patients. The correct choice states this and ties the selection to the patient's risk level.

Option A: Option A is incorrect because raising blood pressure does nothing to prevent clots and is not indicated.
Option B: Option B is incorrect because bone-modifying therapy, while sometimes used in myeloma for skeletal disease, does not address the thrombosis risk this question targets.
Option D: Option D is incorrect because antihistamines do not prevent venous clots.
Option E: Option E is incorrect because adding a second immunomodulatory drug would compound the clot risk rather than counter it.

13. When a BRAF inhibitor is given alone for BRAF V600E melanoma, some patients develop new skin squamous-cell cancers, driven by the same paradoxical pathway activation seen in normal skin cells. In current practice a MEK inhibitor (a drug acting one step downstream in the same pathway) is routinely added. Besides improving cancer control, what effect does adding the MEK inhibitor have on this skin toxicity?

A) It increases the rate of secondary skin cancers and requires closer dermatologic surveillance
B) It reduces the rate of these secondary skin cancers by suppressing the paradoxical pathway activation
C) It has no effect on skin cancers but eliminates all other side effects
D) It causes the existing melanoma to convert into a squamous-cell cancer
E) It works only if the patient also stops the BRAF inhibitor entirely

ANSWER: B

Rationale:

This question applies the paradoxical-activation concept established earlier to a combination-therapy decision. The secondary squamous-cell skin cancers seen with BRAF inhibitor monotherapy arise because the drug paradoxically activates the growth pathway in cells with normal BRAF; blocking the pathway one step downstream with a MEK inhibitor suppresses that activation, so adding the MEK inhibitor markedly reduces these skin lesions while also improving tumor control. This is what the correct choice states.

Option A: Option A is incorrect because it inverts the effect — the combination lowers, not raises, the rate of these lesions.
Option C: Option C is incorrect because the MEK inhibitor specifically does reduce the skin cancers and does not eliminate all other toxicities.
Option D: Option D is incorrect because drugs do not transform melanoma into squamous-cell carcinoma.
Option E: Option E is incorrect because the benefit comes from combining the two drugs, not from stopping the BRAF inhibitor.

14. Venetoclax is broken down by the liver enzyme CYP3A4 (a major drug-metabolizing enzyme). Many patients also take azole antifungal drugs, which strongly block CYP3A4. Connecting this interaction to what you already know about venetoclax, why is starting a strong CYP3A4 inhibitor during the venetoclax dose ramp-up especially hazardous?

A) It speeds venetoclax breakdown, making the drug ineffective and allowing the cancer to grow
B) It has no meaningful effect because venetoclax is cleared unchanged by the kidney
C) It neutralizes the antifungal, exposing the patient to infection
D) It converts venetoclax into an inactive metabolite that accumulates harmlessly
E) It sharply raises venetoclax blood levels, increasing tumor cell killing and the risk of tumor lysis syndrome

ANSWER: E

Rationale:

This question links a pharmacokinetic interaction to a clinical danger already established for venetoclax. Because CYP3A4 clears venetoclax, a strong inhibitor of that enzyme causes venetoclax levels to rise several-fold; during the ramp-up phase, when tumor burden and tumor-lysis risk are highest, that surge in drug level intensifies simultaneous tumor cell death and can precipitate tumor lysis syndrome — which is why strong CYP3A4 inhibitors are avoided or the venetoclax dose is reduced. This is what the correct choice captures.

Option A: Option A is incorrect because an inhibitor slows breakdown and raises levels, the opposite of speeding clearance.
Option B: Option B is incorrect because venetoclax is not renally cleared unchanged; it is metabolized by CYP3A4, so the interaction is significant.
Option C: Option C is incorrect because venetoclax does not inactivate the antifungal — the concern runs the other way.
Option D: Option D is incorrect because the inhibitor raises active drug exposure rather than producing a harmless inactive metabolite.

15. Idelalisib blocks PI3K-delta, the form of the enzyme that B lymphocytes use for survival signaling. Because this same signaling is part of normal immune function, idelalisib carries an excess risk of opportunistic infections, including a specific pneumonia caused by an organism that mainly threatens immunosuppressed patients. What preventive measure is therefore mandatory during idelalisib therapy?

A) Daily aspirin to prevent clots
B) A statin to lower cholesterol
C) Routine iron supplementation
D) Prophylaxis against Pneumocystis jirovecii pneumonia, typically with trimethoprim-sulfamethoxazole
E) A proton pump inhibitor to protect the stomach

ANSWER: D

Rationale:

This question connects the drug's mechanism to a required preventive prescription. By blocking PI3K-delta, idelalisib suppresses normal immune signaling and raises the risk of opportunistic infection, notably Pneumocystis jirovecii pneumonia; for this reason prophylaxis against that organism — usually trimethoprim-sulfamethoxazole, with alternatives for sulfa-allergic patients — is mandatory, along with monitoring for cytomegalovirus reactivation. This required measure is the one given in the correct choice.

Option A: Option A is incorrect because clot prevention is not the infection-related need this drug creates.
Option B: Option B is incorrect because cholesterol lowering does not address opportunistic infection risk.
Option C: Option C is incorrect because iron supplementation is unrelated to the immunosuppression concern.
Option E: Option E is incorrect because gastric protection does not prevent the pneumonia that idelalisib predisposes to.

16. Earlier you encountered two distinct emergencies: tumor lysis syndrome with venetoclax and differentiation syndrome with IDH inhibitors. A student is asked to explain why these two syndromes arise from opposite cellular events. Which statement correctly distinguishes them?

A) Tumor lysis syndrome results from rapid tumor cell death; differentiation syndrome results from leukemic cells being forced to mature
B) Both result from rapid tumor cell death and differ only in which electrolyte rises
C) Differentiation syndrome results from cell death, while tumor lysis syndrome results from cells maturing
D) Both result from cells maturing and differ only in the organ affected
E) Neither is related to the drug's mechanism; both are random allergic events

ANSWER: A

Rationale:

This bridge question requires discriminating between two previously established concepts using their underlying mechanisms. Venetoclax triggers rapid, synchronous tumor cell death, spilling intracellular contents and producing tumor lysis syndrome; IDH inhibitors instead force leukemic blasts to mature, and that wave of differentiation releases inflammatory mediators, producing differentiation syndrome. The two arise from opposite cellular events — death versus maturation. The correct choice states this accurately.

Option B: Option B is incorrect because the two syndromes do not share the cell-death mechanism; only tumor lysis does.
Option C: Option C is incorrect because it reverses the two mechanisms.
Option D: Option D is incorrect because tumor lysis is not a maturation phenomenon.
Option E: Option E is incorrect because both syndromes are direct, predictable consequences of their respective drug mechanisms, not random allergic reactions.

17. You learned that ibrutinib is characteristically associated with atrial fibrillation, attributed to its off-target kinase effects, and that the second-generation BTK inhibitors acalabrutinib and zanubrutinib are more selective for BTK. A patient with chronic lymphocytic leukemia who has a history of atrial fibrillation needs a BTK inhibitor. Applying what you know about selectivity, which choice is most appropriate and why?

A) Ibrutinib, because its off-target effects protect the heart
B) Any BTK inhibitor, because they are identical in cardiac risk
C) A more selective second-generation agent (acalabrutinib or zanubrutinib), because greater BTK selectivity is associated with less atrial fibrillation
D) No BTK inhibitor can ever be used once atrial fibrillation has occurred
E) Ibrutinib at a higher dose, to overwhelm the arrhythmia

ANSWER: C

Rationale:

This bridge question applies the established link between off-target kinase inhibition and atrial fibrillation to a selection decision. Because ibrutinib's atrial fibrillation is attributed to its off-target activity, the more selective second-generation agents acalabrutinib and zanubrutinib carry a lower rate of atrial fibrillation and are preferred when arrhythmia or a need for anticoagulation is a concern. The correct choice gives both the agent and the selectivity-based reasoning.

Option A: Option A is incorrect because ibrutinib's off-target effects cause, rather than protect against, the arrhythmia.
Option B: Option B is incorrect because the agents differ meaningfully in cardiac risk — that difference is the point.
Option D: Option D is incorrect because BTK inhibitors can still be used; the strategy is to choose a more selective agent and manage the rhythm.
Option E: Option E is incorrect because raising the ibrutinib dose would increase, not overcome, the arrhythmia risk.

18. Among the proteasome inhibitors, bortezomib is injected and is limited by peripheral neuropathy, while ixazomib belongs to the same class but has a feature that makes it attractive for outpatient management and for patients in whom neuropathy is a concern. Applying what you know about these agents, what distinguishes ixazomib?

A) It is the only proteasome inhibitor given by continuous intravenous infusion
B) It is taken by mouth, allowing convenient outpatient dosing, and tends to cause less peripheral neuropathy than bortezomib
C) It is the most cardiotoxic proteasome inhibitor and requires intensive cardiac monitoring
D) It is not a proteasome inhibitor at all and works by a different mechanism
E) It must always be combined with bortezomib to be effective

ANSWER: B

Rationale:

This bridge question asks the student to discriminate among three related agents using properties built earlier in the set. Ixazomib is the oral proteasome inhibitor, which enables convenient outpatient, once-weekly dosing and pairs well with oral immunomodulatory drugs; its tolerability is favorable, with less peripheral neuropathy than bortezomib. The correct choice captures both the oral route and the neuropathy advantage.

Option A: Option A is incorrect because ixazomib is oral, not a continuous infusion.
Option C: Option C is incorrect because cardiovascular toxicity is the hallmark of carfilzomib, not ixazomib.
Option D: Option D is incorrect because ixazomib is indeed a proteasome inhibitor, sharing the class mechanism.
Option E: Option E is incorrect because ixazomib does not require co-administration with bortezomib; it is used in its own combinations.

19. Several drugs in this module can only be used after a specific molecular test confirms the target is present — a companion diagnostic. Building on the paradoxical-activation concept you applied earlier, why must BRAF V600E mutation status be confirmed before a BRAF inhibitor is prescribed?

A) Because the test determines the correct intravenous infusion rate
B) Because insurance billing codes require a genetic test for all oral drugs
C) Because the test predicts which antibiotic prophylaxis to use
D) Because the drug benefits V600E-mutant tumors but can paradoxically accelerate growth in tumors lacking that mutation, so confirming the target prevents harm
E) Because the test is only used to estimate prognosis and does not affect the treatment decision

ANSWER: D

Rationale:

This bridge question reapplies the paradoxical-activation principle to the logic of companion diagnostics. A BRAF inhibitor is beneficial when the tumor truly carries the V600E mutation, but in a tumor lacking that mutation — particularly one with a RAS mutation — the same drug can paradoxically activate the growth pathway and accelerate the cancer. Confirming V600E status before prescribing ensures the drug is given only where it helps and not where it harms. This reasoning is the one given in the correct choice.

Option A: Option A is incorrect because the test identifies a molecular target, not an infusion rate, and these agents are oral.
Option B: Option B is incorrect because the requirement is driven by safety and efficacy, not billing.
Option C: Option C is incorrect because the mutation test does not select antimicrobial prophylaxis.
Option E: Option E is incorrect because the test directly governs whether the drug should be used at all — it is far more than a prognostic marker.

20. Many of the oral targeted drugs in this module — CDK4/6 inhibitors, BTK inhibitors, venetoclax, and others — are broken down by the same liver enzyme, CYP3A4. Applying this shared property, what general rule should a clinician keep in mind when one of these drugs is combined with a strong CYP3A4 inhibitor versus a strong CYP3A4 inducer?

A) Inhibitors and inducers both lower the drug level equally
B) Inhibitors lower the drug level, risking treatment failure; inducers raise it, risking toxicity
C) Neither inhibitors nor inducers change the drug level, since CYP3A4 is not involved in clearance
D) Inhibitors and inducers both raise the drug level equally
E) A strong inhibitor raises the drug level and risks toxicity, while a strong inducer lowers it and risks loss of efficacy

ANSWER: E

Rationale:

This bridge question generalizes a pharmacokinetic principle across the whole module. Because these agents are CYP3A4 substrates, a strong CYP3A4 inhibitor slows their breakdown and raises blood levels, increasing the risk of toxicity, whereas a strong CYP3A4 inducer speeds breakdown and lowers levels, risking loss of efficacy — so inhibitors typically prompt dose reduction and inducers are generally avoided. The correct choice states this relationship accurately.

Option A: Option A is incorrect because inhibitors and inducers act in opposite directions, not the same one.
Option B: Option B is incorrect because it reverses the effects of inhibitors and inducers.
Option C: Option C is incorrect because CYP3A4 is precisely the enzyme that clears these drugs, so these interactions are clinically important.
Option D: Option D is incorrect because inducers lower, not raise, drug levels.

21. A student is given three findings and asked to match each to its most characteristic drug: (1) a rise in blood glucose from impaired insulin signaling, (2) fever with breathlessness and lung infiltrates from forced blast maturation, and (3) a metabolic crisis from rapid simultaneous tumor cell death. Using the mechanisms established earlier, which matching is correct?

A) Hyperglycemia with alpelisib; differentiation syndrome with an IDH inhibitor; tumor lysis syndrome with venetoclax
B) Hyperglycemia with venetoclax; differentiation syndrome with alpelisib; tumor lysis syndrome with an IDH inhibitor
C) Hyperglycemia with an IDH inhibitor; differentiation syndrome with venetoclax; tumor lysis syndrome with alpelisib
D) All three findings are caused by the same drug
E) None of these findings is linked to any specific drug mechanism

ANSWER: A

Rationale:

This bridge question requires the student to reassemble three mechanism-to-toxicity links built earlier in the set. Alpelisib blocks PI3K-alpha, the enzyme insulin uses for glucose uptake, producing hyperglycemia; IDH inhibitors force leukemic blasts to mature, producing differentiation syndrome with fever, dyspnea, and infiltrates; venetoclax causes rapid synchronous tumor cell death, producing tumor lysis syndrome. Option A matches each finding to the correct drug.

Option B: Option B is incorrect because it scrambles all three pairings.
Option C: Option C is incorrect because it also misassigns each mechanism to the wrong drug.
Option D: Option D is incorrect because these are three distinct drugs with three distinct mechanisms, not one.
Option E: Option E is incorrect because each finding is a direct, well-established consequence of its drug's mechanism.

22. Returning to the synthetic-lethality concept: a PARP inhibitor is being considered for two patients. Patient 1 has a tumor with a BRCA mutation (the back-up homologous-recombination repair system is lost). Patient 2 has a tumor with fully intact BRCA-dependent repair. Applying what you learned about synthetic lethality, which patient's tumor is expected to be selectively vulnerable to the PARP inhibitor, and why?

A) Patient 2, because intact repair makes the tumor more sensitive to losing PARP
B) Patient 1, because the tumor has already lost its back-up repair system, so removing PARP leaves it unable to fix DNA and it dies
C) Both equally, because PARP inhibitors act independently of repair status
D) Neither, because PARP inhibitors only work in tumors with no mutations at all
E) Patient 2, because the drug restores BRCA function only when repair is already intact

ANSWER: B

Rationale:

This final bridge question reapplies the synthetic-lethality principle to a selection decision. Patient 1's BRCA-mutant tumor has already lost its homologous-recombination back-up pathway and depends on PARP-mediated repair to survive; removing PARP leaves it with no way to repair accumulating DNA damage, so it dies selectively. Patient 2's tumor retains intact BRCA-dependent repair and therefore tolerates PARP inhibition, just as normal cells do. The correct choice identifies the vulnerable patient and the reason.

Option A: Option A is incorrect because intact repair confers resistance, not sensitivity, to PARP inhibition.
Option C: Option C is incorrect because the entire selectivity of these drugs depends on repair status — which is why BRCA and homologous-recombination testing guides their use.
Option D: Option D is incorrect because PARP inhibitors specifically exploit a repair-deficient state rather than requiring a mutation-free tumor.
Option E: Option E is incorrect because PARP inhibitors do not restore BRCA function; their selectivity arises when that function is absent.